Natural killer (NK) cells represent an important class of immune cells involved in anti-tumor immunity. Once identifying a tumor cell, NK cells use small particles to kill the cancer cell.
Our understanding of the role of NK cells in anti-tumor immunity has led to the development of techniques that transfer NK cells from a healthy individual into a cancer patient. Such approaches, known as allogeneic NK cell adoptive transfer, have effectively treated certain types of leukemia and lymphoma. While such strategies can induce remission, clinical challenges about the survival and function of the transferred NK cells exist. Thus, research focused on enhancing the ability of transferred NK cells to survive and maintain their ability to function has become highly valuable in an effort to provide new, efficacious therapeutic options.
A new report published in Science Translational Medicine finds that a vitamin supplement could effectively improve the efficacy of NK cell adoptive transfer treatment. Supported by pre-clinical studies, the investigators conducted a phase 1 clinical trial to test a new method for processing NK cells before transferring them to a patient.
Comments are closed.